These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 25976187

  • 1. Aceruloplasminaemia: a rare but important cause of iron overload.
    Doyle A, Rusli F, Bhathal P.
    BMJ Case Rep; 2015 May 14; 2015():. PubMed ID: 25976187
    [Abstract] [Full Text] [Related]

  • 2. Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation.
    Skidmore FM, Drago V, Foster P, Schmalfuss IM, Heilman KM, Streiff RR.
    J Neurol Neurosurg Psychiatry; 2008 Apr 14; 79(4):467-70. PubMed ID: 17911185
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Iron chelation therapy to prevent the manifestations of aceruloplasminemia.
    Bove F, Fasano A.
    Neurology; 2015 Sep 22; 85(12):1085-6. PubMed ID: 26311749
    [No Abstract] [Full Text] [Related]

  • 6. Combination-therapy with concurrent deferoxamine and deferiprone is effective in treating resistant cardiac iron-loading in aceruloplasminaemia.
    Badat M, Kaya B, Telfer P.
    Br J Haematol; 2015 Nov 22; 171(3):430-2. PubMed ID: 25855051
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
    Ladis V, Berdousi H, Gotsis E, Kattamis A.
    Br J Haematol; 2010 Dec 22; 151(5):504-8. PubMed ID: 20950401
    [Abstract] [Full Text] [Related]

  • 10. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN, El Rassi F, Taher AT.
    Expert Rev Hematol; 2016 Dec 22; 9(2):151-68. PubMed ID: 26613264
    [Abstract] [Full Text] [Related]

  • 11. Novel ceruloplasmin mutation causing aceruloplasminemia with hepatic iron overload and diabetes without neurological symptoms.
    Rusticeanu M, Zimmer V, Schleithoff L, Wonney K, Viera J, Zimmer A, Hübschen U, Bohle RM, Grünhage F, Lammert F.
    Clin Genet; 2014 Mar 22; 85(3):300-1. PubMed ID: 23557349
    [No Abstract] [Full Text] [Related]

  • 12. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
    Porter JB, Shah FT.
    Hematol Oncol Clin North Am; 2010 Dec 22; 24(6):1109-30. PubMed ID: 21075283
    [Abstract] [Full Text] [Related]

  • 13. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan 22; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

  • 14. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009 Jan 22; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 15. Diagnosing aceruloplasminemia: navigating through red herrings.
    Kharel Z, Kharel H, Phatak PD.
    Ann Hematol; 2024 Jun 22; 103(6):2173-2176. PubMed ID: 38637332
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
    Karimi M, Arandi N, Haghpanah S, Ansari S, Azarkeyvan A, Bordbar M, Safaei S.
    Hemoglobin; 2015 Jun 22; 39(5):327-9. PubMed ID: 26114738
    [Abstract] [Full Text] [Related]

  • 18. Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation.
    Mariani R, Arosio C, Pelucchi S, Grisoli M, Piga A, Trombini P, Piperno A.
    Gut; 2004 May 22; 53(5):756-8. PubMed ID: 15082597
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S, Ebadi M, Ghazizadeh F, Arzanian MT, Shamsian B, Abdollah Gorji F.
    Pediatr Hematol Oncol; 2014 Feb 22; 31(1):76-86. PubMed ID: 24383712
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.